D-cycloserine Augmented CBT for Panic Disorder
Phase 3
Terminated
- Conditions
- Panic Disorder
- Interventions
- Registration Number
- NCT01680107
- Lead Sponsor
- University of Oxford
- Brief Summary
The purpose of this study is to determine whether d-cycloserine augments the clinical effects of exposure-based cognitive-behaviour therapy for panic disorder.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
- clinical diagnosis of panic disorder
- at least moderate agoraphobic avoidance
Exclusion Criteria
- psychoactive medication last 6 weeks
- exposure-based cognitive-behaviour treatment for panic disorder and agoraphobia during last 3 months
- female participant who is pregnant or breast-feeding
- lifetime history of psychosis, bipolar disorder, alcohol, medication or drug abuse or dependence; current primary depressive disorder
- lifetime history of epilepsy or other significant disease or disorder
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description d-cycloserine cognitive-behaviour therapy oral, capsule, 250 mg, once d-cycloserine d-cycloserine oral, capsule, 250 mg, once sugar pill placebo oral, capsule, once sugar pill cognitive-behaviour therapy oral, capsule, once
- Primary Outcome Measures
Name Time Method self-reported and clinician-rated anxiety and depression measures 6 months
- Secondary Outcome Measures
Name Time Method emotional information processing 1 day
Trial Locations
- Locations (1)
Department of Psychiatry, University of Oxford
🇬🇧Oxford, United Kingdom